The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience

• Published in: Renal failure Vol. 46; no. 2; p. 2385724
• Main Authors: Zhang, Huanxi, Wu, Wenrui, Zheng, Yitao, Fu, Qian, Chen, Peisong, Li, Jianyi, Wu, Zixuan, Gu, Jincui, Li, Jun, Liu, Longshan, Wu, Chenglin, Long, Sizhe, Xu, Bowen, Ling, Liuting, Fu, Yingxin, Wang, Changxi
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Ltd 01.12.2024; Taylor & Francis; Taylor & Francis Group
• Subjects: Adult; Aged; Antimetabolites; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Calcineurin inhibitors; Corticosteroids; COVID-19; COVID-19 - complications; COVID-19 - mortality; COVID-19 Drug Treatment; Dialysis; Drug Combinations; efficacy; Female; Hospitalization - statistics & numerical data; Humans; Immunosuppressive agents; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Intravenous administration; Kidney Transplantation; Lopinavir - administration & dosage; Lopinavir - therapeutic use; Male; Mechanical ventilation; Middle Aged; Mortality; Nirmatrelvir/ritonavir; Patients; Retrospective Studies; Ritonavir; Ritonavir - administration & dosage; Ritonavir - therapeutic use; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Steroids; Transplant Recipients - statistics & numerical data; Transplantation; Treatment Outcome; COVID-19; SARS-CoV-2; Nirmatrelvir/ritonavir; efficacy; kidney transplantation

Effectiveness of nirmatrelvir/ritonavir (NR) in kidney transplant recipients (KTRs) infected COVID-19 for more than 5 days has not been evaluated. In this multicenter retrospective study, 85 KTRs with COVID-19 were enrolled, including 50 moderate, 21 severe, and 14 critical patients. The median time...